
Allyson Hart

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8864433/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	New National Allocation Policy for Deceased Donor Kidneys in the United States and Possible Effect on Patient Outcomes. Journal of the American Society of Nephrology: JASN, 2014, 25, 1842-1848.	6.1	338
2	Cardiovascular risk assessment in kidney transplantation. Kidney International, 2015, 87, 527-534.	5.2	70
3	Incidence, risk factors, treatment, and consequences of antibodyâ€mediated kidney transplant rejection: A systematic review. Clinical Transplantation, 2021, 35, e14320.	1.6	32
4	Beyond "Median Waiting Time― Transplantation, 2016, 100, 1564-1570.	1.0	31
5	Cystatin <scp>C</scp> and Frailty in Older Men. Journal of the American Geriatrics Society, 2013, 61, 1530-1536.	2.6	27
6	Prediction of Risk of Death for Patients Starting Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 1213-1227.	4.5	26
7	Predicting Outcomes on the Liver Transplant Waiting List in the United States. Transplantation, 2016, 100, 2153-2159.	1.0	25
8	Mortality among solid organ waitlist candidates during COVID-19 in the United States. American Journal of Transplantation, 2021, 21, 2262-2268.	4.7	24
9	Decision support needs of kidney transplant candidates regarding the deceased donor waiting list: A qualitative study and conceptual framework. Clinical Transplantation, 2019, 33, e13530.	1.6	23
10	Non–Vitamin K–Dependent Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With CKD: Pragmatic Considerations for the Clinician. American Journal of Kidney Diseases, 2018, 72, 717-727.	1.9	19
11	Uric Acid and Allograft Loss From Interstitial Fibrosis/Tubular Atrophy. Transplantation, 2014, 97, 1066-1071.	1.0	16
12	The association between loss of Medicare, immunosuppressive medication use, and kidney transplant outcomes. American Journal of Transplantation, 2019, 19, 1964-1971.	4.7	14
13	Recommendations for kidney disease guideline updating: a report by the KDIGO Methods Committee. Kidney International, 2016, 89, 753-760.	5.2	13
14	Cystatin C and the Risk of Frailty and Mortality in Older Men. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2017, 72, glw223.	3.6	12
15	Cardiovascular protection and mounting evidence for the benefits of intradialytic exercise. Nephrology Dialysis Transplantation, 2019, 34, 1816-1818.	0.7	7
16	Incidence, risk factors, and longâ€term outcomes associated with antibodyâ€mediated rejection — The longâ€term Deterioration of Kidney Allograft Function (DeKAF) prospective cohort study. Clinical Transplantation, 2021, 35, e14337.	1.6	6
17	Balancing uncertain risks in candidates for solid organ transplantation with a history of malignancy: Who is safe to transplant?. American Journal of Transplantation, 2021, 21, 447-448.	4.7	5
18	Identifying Needs and Barriers to Engage Family Members in Transplant Candidate Care. Progress in Transplantation, 2021, 31, 142-151.	0.7	5

Allyson Hart

#	Article	IF	CITATIONS
19	Solid Organ Transplantation and Survival among Individuals with a History of Cancer. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1312-1319.	2.5	5
20	The Cost of Screening Kidney Transplant Candidates for Coronary Artery Disease. American Journal of Kidney Diseases, 2020, 75, 684-686.	1.9	5
21	Renal Function and Death in Older Women: Which eGFR Formula Should We Use?. International Journal of Nephrology, 2017, 2017, 1-10.	1.3	4
22	Equity in kidney transplantation: Policy change is only the first step. American Journal of Transplantation, 2018, 18, 1839-1840.	4.7	4
23	Predicted Cure and Survival Among Transplant Recipients With a Previous Cancer Diagnosis. Journal of Clinical Oncology, 2021, , JCO2101195.	1.6	4
24	Kidney-Metabolic Factors Associated with Cognitive Impairment in Chronic Kidney Disease: A Pilot Study. American Journal of Nephrology, 2022, 53, 435-445.	3.1	4
25	Cost, healthcare utilization, and outcomes of antibody-mediated rejection in kidney transplant recipients in the US. Journal of Medical Economics, 2021, 24, 1011-1017.	2.1	3
26	Cost burden of post-transplant lymphoproliferative disease following kidney transplants in Medicare-eligible patients by survival status. Journal of Medical Economics, 2021, 24, 620-627.	2.1	2
27	Journey to Transplant: Developing a social support network counselling intervention to improve kidney transplantation. Health Expectations, 2022, 25, 648-658.	2.6	2
28	Toward continuous improvement of Scientific Registry of Transplant Recipients performance reporting: Advances following 2012 consensus conference and future consensus building for 2022 consensus conference. Clinical Transplantation, 0, , .	1.6	2
29	The Authors Reply:. Kidney International, 2015, 87, 863-864.	5.2	0
30	Routine Cardiac Stress Testing in Potential Kidney Transplant Candidates Is Only Appropriate in Symptomatic Individuals: COMMENTARY. Kidney360, 2022, 3, 2017-2018.	2.1	0